Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond
Seminars in Liver Disease · 01.05.2023 · 43 (02) · 218-225
DOI: 10.1055/a-2049-3149 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.05.2023. Verfasst von Pedro Luiz Serrano Uson Junior und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Fibroblast growth factor receptor 2 (FGFR2) inhibitors are now being included in the treatment guidelines of multiple countries for patients with advanced cholangiocarcinoma (CCA). Activation of the FGF–FGFR pathway is related to proliferation and tumor progression. Targeting the FGF–FGFR pathway is effective and can yield durable responses in patients with CCA harboring FGFR2 fusions or rearrangements. In this review article, we address molecules and clinical trials evaluating FGFR inhibitors in advanced CCA. We will further discuss identified mechanisms of resistance and the strategies to overcome it. The incorporation of next-generation sequencing in advanced CCA and circulating tumor DNA on disease progression will unveil mechanisms of resistance and improve the development of future clinical trials and more selective drugs and combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona.
- Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.
- Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
- Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.
- Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona.
Zitieren
APA
Uson Junior, P. L. S., & Borad, M. J. (2023). Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond. Seminars in Liver Disease, 43(02), 218-225. https://doi.org/10.1055/a-2049-3149
Vancouver
Uson Junior PLS, Borad MJ. Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond. Seminars in Liver Disease. 2023;43(02):218-225. doi:10.1055/a-2049-3149
BibTeX
@article{UsonJunior2023,
author = {Uson Junior, Pedro Luiz Serrano and Borad, Mitesh J},
title = {Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond},
journal = {Seminars in Liver Disease},
year = {2023},
volume = {43},
number = {02},
pages = {218--225},
doi = {10.1055/a-2049-3149}
}
EUVIMED